Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Phase I first-in-human study of alnuctamab in patients with R/R multiple myeloma

In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, provides an update on the results of the Phase I CC-93269-MM-001 trial (NCT03486067), which is investigating the safety and efficacy of alnuctamab in patients with relapsed/refractory (R/R) multiple myeloma (MM). Results demonstrated that subcutaneous administration of alnuctamab has an encouraging safety profile in regards to cytokine release syndrome (CRS), with high activity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.